Is plasma ET-1 a marker of vascular complications in type 2 diabetes mellitus?

被引：0
|
作者：
Sármán, B
Tóth, M
Kocsis, I
Somogyi, A
机构：
[1] Semmelweis Univ Med, Dept Med 2, H-1085 Budapest, Hungary
[2] Semmelweis Univ Med, Dept Med 1, H-1085 Budapest, Hungary
来源：
DIABETOLOGIA | 1999年 / 42卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1213
引用
收藏
页码：A320 / A320
页数：1
相关论文
共 50 条
  • [1] The plasma NO/ET-1 ratio is a useful marker for the grade of coronary vascular disease
    Kurita, A
    Takase, B
    Ishizuka, T
    Hagisawa, K
    Matsui, T
    [J]. EUROPEAN HEART JOURNAL, 2002, 23 : 590 - 590
  • [2] Glycaemic Control and Vascular Complications in Diabetes Mellitus Type 2
    Maranta, Francesco
    Cianfanelli, Lorenzo
    Cianflone, Domenico
    [J]. DIABETES: FROM RESEARCH TO CLINICAL PRACTICE, VOL 4, 2021, 1307 : 129 - 152
  • [3] Ischemia Modified Albumin (IMA) - A Marker of Glycaemic Control and Vascular Complications in Type 2 Diabetes Mellitus
    Chawla, Rajinder
    Loomba, Rinchu
    Guru, Deepak
    Loomba, Vikas
    [J]. JOURNAL OF CLINICAL AND DIAGNOSTIC RESEARCH, 2016, 10 (03) : BC13 - BC16
  • [4] Plasma thrombomodulin: A marker for microvascular complications in diabetes mellitus
    Gabat, S
    Keller, C
    Kempe, HP
    Amiral, J
    Ziegler, R
    Ritz, E
    Bergis, KH
    Wahl, P
    Nawroth, P
    [J]. VASA-JOURNAL OF VASCULAR DISEASES, 1996, 25 (03): : 233 - 241
  • [5] sIL-2R plasma levels as a potential marker for progression to vascular complications in patients with type 1 diabetes
    Keindl, M.
    Fedotkina, A.
    du Plessis, E.
    Jain, R.
    Bergum, B.
    Falhammar, H.
    Nystrom, T.
    Catrina, S. -B.
    Groop, L.
    Eliasson, M.
    Eliasson, B.
    Nilsson, P. M.
    Berg, T. J.
    Appel, S.
    Lyssenko, V.
    [J]. DIABETOLOGIA, 2019, 62 : S36 - S36
  • [6] Screening for vascular complications in children and adolescents with type 1 diabetes mellitus
    Chiarelli, F
    Mohn, A
    Tumini, S
    Trotta, D
    Verrotti, A
    [J]. HORMONE RESEARCH, 2002, 57 : 113 - 116
  • [7] The phosphodiesterase-5 inhibitor tadalafil decreases ET-1 expression in HUVECs and suppresses circulating ET-1 levels type 2 diabetes mellitus patients
    Olausson, J.
    Sjogren, L.
    Hulten, L. Mattsson
    Jansson, P. A.
    [J]. DIABETOLOGIA, 2013, 56 : S519 - S520
  • [8] Recent Updates on Vascular Complications in Patients with Type 2 Diabetes Mellitus
    Jung, Chan-Hee
    Mok, Ji-Oh
    [J]. ENDOCRINOLOGY AND METABOLISM, 2020, 35 (02) : 260 - 271
  • [9] The Contribution of Wnt Signaling to Vascular Complications in Type 2 Diabetes Mellitus
    Sanabria-de la Torre, Raquel
    Garcia-Fontana, Cristina
    Gonzalez-Salvatierra, Sheila
    Andujar-Vera, Francisco
    Martinez-Heredia, Luis
    Garcia-Fontana, Beatriz
    Munoz-Torres, Manuel
    [J]. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2022, 23 (13)
  • [10] Serum Angiopoietin-2 levels as a marker in type 2 diabetes mellitus complications
    Khalid Siddiqui
    Salini Scaria Joy
    Shaik Sarfaraz Nawaz
    [J]. International Journal of Diabetes in Developing Countries, 2019, 39 : 387 - 393
12345